Literature DB >> 29270884

Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?

Pedro Góes1, Bruno Fernandes Oliveira Santos2, Fernando Seiji Suzuki2, Débora Salles3, João Noberto Stávale3, Sérgio Cavalheiro2, Manoel Antônio de Paiva Neto2.   

Abstract

The purpose of this study was to evaluate spontaneous necrosis as a possible isolated factor for progression and recurrence in grade I meningiomas classified according to the current World Health Organization (WHO) classification. Meningiomas are the most frequently reported primary intracranial tumours, accounting for more than 35%. The 2016 WHO classification of central nervous system tumors stratifies meningiomas in grades I (benign), II (atypical), and III (malignant), according to histopathological aspects and the risk of progression or recurrence. Among 110 patients with intracranial meningiomas, 70 were WHO grade I meningiomas with no findings of atypia (G1WON), 15 were WHO grade I with necrosis (G1WN), 21 were WHO grade II (G2), and 4 were WHO grade III (G3). The mean follow-up was 5.9 ± 0.2 years. High performance scale (KPS ≥ 80) was different (p < 0.001) between WHO grade I meningiomas without (81.4%) and with (60%) necrosis. The 5-year mortality rate was 1.4, 6.7 and 5.9% for G1WON, G1WN and G2, respectively, with significant difference (p = 0.011) related to the presence of necrosis. The risk of recurrence was 3.7 times higher in G1WN than in G1WON (p = 0.017), and 4.2 times in G2 (p = 0.010). Progression-free survival (PFS) was clearly higher in patients with G1WON compared to G1WN and G2 (p = 0.002 and p < 0.001, respectively). There was no significant difference in PFS between G1WN and G2 (p = 0.692). Retreatment was also superior in meningioma with necrosis. Our findings provide clear statistical data to consider that patients with benign meningiomas and histologic findings of spontaneous necrosis are at increased risk of progression and recurrence compared to those with benign lesion without atypical features. Statistical analysis curves also suggest that these lesions behave more similarly to those currently classified as WHO grade II meningioma.

Entities:  

Keywords:  Atypical; Meningioma; Necrosis; Progression

Mesh:

Year:  2017        PMID: 29270884     DOI: 10.1007/s11060-017-2721-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  26 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordonna Fulop; Max Liu; Rachel Blanda; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-10-27       Impact factor: 12.300

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.

Authors:  John S Lam; Oleg Shvarts; Jonathan W Said; Allan J Pantuck; David B Seligson; Michael E Aldridge; Matthew H T Bui; Xueli Liu; Steve Horvath; Robert A Figlin; Arie S Belldegrun
Journal:  Cancer       Date:  2005-06-15       Impact factor: 6.860

5.  Meningioma grading: an analysis of histologic parameters.

Authors:  A Perry; S L Stafford; B W Scheithauer; V J Suman; C M Lohse
Journal:  Am J Surg Pathol       Date:  1997-12       Impact factor: 6.394

6.  Atypical (anaplastic) meningioma: relationship between histologic features and recurrence--a clinicopathologic study.

Authors:  W Y Chen; H C Liu
Journal:  Clin Neuropathol       Date:  1990 Mar-Apr       Impact factor: 1.368

7.  Vascular proliferation is important for clinical progress of endometrial cancer.

Authors:  Ingunn M Stefansson; Helga B Salvesen; Lars A Akslen
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

8.  Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma.

Authors:  John G Edwards; Daniel E B Swinson; J Louise Jones; Salli Muller; David A Waller; Kenneth J O'Byrne
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  2 in total

1.  Malignant transformation of WHO grade I meningiomas after surgery or radiosurgery: systematic review and meta-analysis of observational studies.

Authors:  Satoshi Nakasu; Akifumi Notsu; Kiyong Na; Yoko Nakasu
Journal:  Neurooncol Adv       Date:  2020-10-16

2.  Tumor-associated macrophage infiltration in meningioma.

Authors:  Dustin T Proctor; Jordan Huang; Sanju Lama; Abdulrahman Albakr; Guido Van Marle; Garnette R Sutherland
Journal:  Neurooncol Adv       Date:  2019-09-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.